强骨饮治疗绝经后骨质疏松症的临床研究

目的：观察与评价强骨饮治疗绝经后骨质疏松症（PMOP）的临床疗效及安全性，并初步探讨其作用机制。方法将90例PMOP患者随机分为强骨饮组，基础用药组和仙灵骨葆组，每组30例。基础用药组口服碳酸钙D3和阿法骨化醇；仙灵骨葆组在基础用药组的基础上加仙灵骨葆口服；强骨饮组在基础用药组的基础上加强骨饮口服。均经6个月治疗后观察各组骨密度、骨转化指标、VAS及SF-36评分。结果治疗6个月后，各组VAS及SF-36评分均有变化（P〈0.05）；强骨饮组和仙灵骨葆组经治疗后骨密度和骨转化指标均有改变，优于基础用药组（P〈0.05）。结论强骨饮不仅能有效减轻PMOP患者疼痛，而且可提高患者骨密度，提升生存质量，降低骨转化指标。

Clinical Study of Qiangguyin for Treating Postmenopausal Osteoporosis

Objective To observe and evaluate the clinical efficacy and safety of the Qiangguyin on postmenopausal osteoporosis （PMOP）, and to explore its mechanism. Methods All 90 patients who meet the inclusion criteria were randomly divided into three groups, namely Qiangguyin group, basic medication group and Xianlinggubao group with 30 cases for each one. Basic medication group was given calcium carbonate D3 tablets and alfacalcidol capsules. Xianlinggubao group was based on basic medication group to plus Xianlinggubao capsules. Qiangguyin group was based on basic medication group to plus Qiangguyin granules. All groups were treated for 6 months. Outcome measures included bone mineral density （BMD）, bone metabolic markers, visual analogue scales （VAS） and SF-36 score. Results After 6 months of treatment , VAS and SF-36 scores of all groups had changes , the difference was statistically significant （P〈0.05）. BMD and bone metabolic markers of Qiangguyin group and Xianlinggubao group after treatment changed, both the groups had advantages over basic medication group （P〈0.05）. Conclusion Qiangguyin is not only able to effectively relieve pain of PMOP, but also promote the bone mineral density. It may improve the quality of life and reduce the bone metabolic markers （PINP and S-CTX）.